# The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)

> **NCT02336568** · PHASE4 · UNKNOWN · sponsor: **Rambam Health Care Campus** · enrollment: 40 (estimated)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** Oxytoine
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT02336568
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2016-12
- **Final completion:** 2018-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336568, "The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02336568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*